

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM493611

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST

## CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Oxford Finance LLC		10/11/2018	Limited Liability Company: DELAWARE

## RECEIVING PARTY DATA

<b>Name:</b>	Acura Pharmaceuticals, Inc.
<b>Street Address:</b>	616 N. North Court, South 120
<b>City:</b>	Palatine
<b>State/Country:</b>	ILLINOIS
<b>Postal Code:</b>	60067
<b>Entity Type:</b>	Corporation: NEW YORK
<b>Name:</b>	Acura Pharmaceutial Teachnologies, Inc.
<b>Street Address:</b>	16235 State Road 17
<b>City:</b>	Culver
<b>State/Country:</b>	INDIANA
<b>Postal Code:</b>	46511
<b>Entity Type:</b>	Corporation: INDIANA

## PROPERTY NUMBERS Total: 5

Property Type	Number	Word Mark
<b>Registration Number:</b>	3114970	ACURA PHARMACEUTICALS
<b>Registration Number:</b>	4847742	OXAYDO
<b>Registration Number:</b>	4151083	NEXAFED
<b>Registration Number:</b>	4289295	IMPEDE
<b>Registration Number:</b>	3059542	AVERSION

## CORRESPONDENCE DATA

Fax Number: 6785532602

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

Phone: (678) 553-2601

Email: jimmarl@gtlaw.com

Correspondent Name: LaShana C. Jimmar, Paralegal

Address Line 1: GREENBERG TRAURIG, LLP

CH \$140.00 3114970

**Address Line 2:** 3333 PIEDMONT ROAD, NE, SUITE 2500  
**Address Line 4:** ATLANTA, GEORGIA 30305

**ATTORNEY DOCKET NUMBER:** 138179.010900

**NAME OF SUBMITTER:** LaShana C. Jimmar

**SIGNATURE:** /LaShana C. Jimmar/

**DATE SIGNED:** 10/11/2018

**Total Attachments: 7**

source=OXFORD - ACURA - Release of Security Interest in Intellectual Property - 10-2018#page1.tif

source=OXFORD - ACURA - Release of Security Interest in Intellectual Property - 10-2018#page2.tif

source=OXFORD - ACURA - Release of Security Interest in Intellectual Property - 10-2018#page3.tif

source=OXFORD - ACURA - Release of Security Interest in Intellectual Property - 10-2018#page4.tif

source=OXFORD - ACURA - Release of Security Interest in Intellectual Property - 10-2018#page5.tif

source=OXFORD - ACURA - Release of Security Interest in Intellectual Property - 10-2018#page6.tif

source=OXFORD - ACURA - Release of Security Interest in Intellectual Property - 10-2018#page7.tif

RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

This RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY is made as of October 11, 2018, by **OXFORD FINANCE LLC**, a Delaware limited liability company, as collateral agent (in such capacity, "Collateral Agent") and as a Lender (the "Lender"), and **ACURA PHARMACEUTICALS, INC.**, a New York corporation and **ACURA PHARMACEUTICAL TECHNOLOGIES, INC.**, an Indiana corporation (individually and collectively, the "Debtors").

WHEREAS, on March 15, 2017, the Debtors granted a continuing and unconditional security interest to the Lender in the following, whether then existing or thereafter arising or acquired: (i) Debtors' copyrights, trademarks, patents and Mask Works set forth on the Exhibits attached hereto, (ii) associated goodwill therein, and (iii) all proceeds and benefits thereof (collectively, the "IP Collateral"), for the purpose of securing certain obligations of the Debtors to the Lender (which such security interest was recorded at the U.S. Patent and Trademark Office at Reel/Frame numbers (41623/0740) and (6014/0910); and

WHEREAS, the Lender desires to release any security interest it might have in the IP Collateral and reassign any and all rights, title and interests in the same to Debtors.

NOW, THEREFORE, for valuable consideration, the receipt and adequacy of which is hereby acknowledged: the Lender hereby (i) unconditionally terminates, releases and discharges any and all security interest, right, title or other interest it may have in the IP Collateral, and (ii) reassigns, grants and conveys to the Debtors, without any recourse, any and all of the Lender's right, title and interest in and to the IP Collateral, along with any goodwill in the trademarks therein that Lender may have acquired.

*[signature page follows]*

IN WITNESS WHEREOF, the undersigned has executed this Release as of the date first written above.

OXFORD FINANCE LLC

By:   
Title: Colette H. Fealherly  
Senior Vice President

EXHIBIT A

Copyrights

Description

Registration/  
Application  
Number

Registration/  
Application  
Date

None

**EXHIBIT B**

Patents

<u>Description</u>	<u>Registration/ Application Number</u>	<u>Registration/ Application Date</u>
Methods and compositions for deterring abuse of opioid containing dosage forms	US 7,201,920	4/10/2007
	US 7,476,402	1/13/2009
	US 7,510,726	3/31/2009
	US 7,981,439	7/19/2011
	US 8,409,616	4/2/2013
	US 8,822,489	7/24/2014
	US 8,637,540	1/28/2014
	US 9,492,443	11/15/2016
	AU 2004294953	4/1/2010
	AU 2010200979	11/23/2004
	CA 2,547,334	8/10/2010
	IL 175863	11/23/2004
	IL 221018	11/23/2004
	US 15/344.631	11/7/2016
	AU 2010200979	3/15/2010
	AU 2013206525	11/23/2004
	EP 04812083.6	11/23/2004
EP 11158284 7	11/23/2011	
HK 12106471.1	11/23/2004	
Process to manufacture oxycodone	US 6,864,370	3/8/2005
Process for manufacturing thebaine	US 6,790,959	9/14/2004
Process for manufacturing codeine	US 6,972,332	12/6/2005
Process for manufacturing codeine	US 6,949,645	9/27/2005
Process for preparing dihydrocodeine from codeine	US 6,887,999	5/3/2005
Preparation of opioid analgesics by a one-pot process	US 6,946,556	9/20/2005
Preparation of oxycodone	US 7,071,336	7/4/2006
Preparation of a 4,5-epoxymorphinan	US 7,348,430	3/25/2008
Methods and compositions for deterring abuse	US 8,901,113	12/2/2104
	AU 2010300641	6/3/2016
	CA 2,775,890	6/21/2016
	EP 2,488,029	3/23/2016
	HK 13102020.5	10/14/2016
	IL 218533	9/29/2016
	US 14/552.067	11/24/2014
US 15/426.296	2/27/2017	

	CA 2,775,890 AU 2016204065 EP 16161681.8 HK 13102020.5 IL 245734	9/29/2010 9/29/2010 9/29/2010 9/29/2010 9/29/2010
Methods and compositions for self-regulated release of active pharmaceutical ingredient	US 9,101,636 US 9,320,796 CA 2,892,908 JP 5,922,851  US 15/074,458 WO PCT/US13/72249 RU 2015124694	8/11/2015 4/26/2016 4/12/2016 4/22/2016  3/18/2016 11/27/2013 6/23/2015
Methods and Compositions for Deterring Abuse	US 14/322,596 CA 2,916,973 AU 2014284333 EP 14820721.0 IL 242880 CH 201480037082.5 NZ 716482	7/2/2014 7/2/2014 7/2/2014 7/2/2014 7/2/2014 7/2/2014 7/2/2014
Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse	US 14/734,364 CA 2,951,563 AU 2015274936 EP 15807096.1 CH 201580030318.7	6/9/2015 6/9/2015 6/9/2015 6/9/2015 6/9/2015
Methods and compositions for self-regulated release of active pharmaceutical	US 15/252,760	8/31/2016
Methods and compositions of self-regulating the conversion of pro-drugs to active pharmaceutical ingredients <sup>22</sup>	US 15/331,643	10/21/2016
Pharmaceutical Compositions for Deterring Misuse, Abuse, and Diversion	WO PCT/US2010/061331	12/20/2010

EXHIBIT C

Trademarks

<u>Description</u>	<u>Registration/ Application Number</u>	<u>Registration/ Application Date</u>
US- ACURA PHARMACEUTICALS	3114970	7/11/2006
US- OXAYDO	4847742	11/3/2015
US- NEXAFED	4151083	4/24/2012
US- IMPEDE	4289295	2/12/2013
US- AVERSION	3059542	2/14/2006
MEX- ACURACET	1087322	2/26/2009
MEX- IMPEDE	1130279	11/13/2009
MEX- ACUROX	1070309	11/4/2008
MEX- AVERSION	1182320	9/30/2010
	1087323	2/26/2009
MEX- VYCAVERT	1109785	7/9/2009
CAN- OXAYDO	1724857	5/23/2016
CAN- AVERSION	832700	9/25/2012
CAN- ACUROX	757997	2/17/2010
CAN- VYCAVERT	825294	6/1/2012
EU- OXAYDO	13955935	8/19/2015



EXHIBIT D

Mask Works

Description

Registration/  
Application/  
Number

Registration/  
Application/  
Date

None